Genmab AS (Denmark) Price Prediction
| GMAB Stock | DKK 1,484 36.00 2.49% |
Oversold Vs Overbought
50
Oversold | Overbought |
Using Genmab AS hype-based prediction, you can estimate the value of Genmab AS from the perspective of Genmab AS response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Genmab AS to buy its stock at a price that has no basis in reality. In that case, they are not buying Genmab because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Genmab AS after-hype prediction price | DKK 1447.5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Genmab |
Genmab AS After-Hype Price Prediction Density Analysis
As far as predicting the price of Genmab AS at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Genmab AS or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Genmab AS, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Genmab AS Estimiated After-Hype Price Volatility
In the context of predicting Genmab AS's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Genmab AS's historical news coverage. Genmab AS's after-hype downside and upside margins for the prediction period are 1,446 and 1,449, respectively. We have considered Genmab AS's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Genmab AS is very steady at this time. Analysis and calculation of next after-hype price of Genmab AS is based on 3 months time horizon.
Genmab AS Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Genmab AS, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.31 | 1.47 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1,484 | 1,448 | 0.00 |
|
Genmab AS Hype Timeline
Genmab AS is currently traded for 1,484on Copenhagen Exchange of Denmark. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Genmab is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at -0.31%. %. The volatility of related hype on Genmab AS is about 0.0%, with the expected price after the next announcement by competition of 1,484. About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.19. Genmab AS recorded earning per share (EPS) of 83.21. The entity had not issued any dividends in recent years. Assuming the 90 days trading horizon the next estimated press release will be in a few days. Check out Genmab AS Basic Forecasting Models to cross-verify your projections. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.Genmab AS Related Hype Analysis
Having access to credible news sources related to Genmab AS's direct competition is more important than ever and may enhance your ability to predict Genmab AS's future price movements. Getting to know how Genmab AS's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Genmab AS may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| AMBU-B | Ambu AS | 0.00 | 0 per month | 0.00 | (0.17) | 2.74 | (4.05) | 21.55 | |
| DSV | DSV Panalpina AS | 0.00 | 0 per month | 0.82 | 0.1 | 2.66 | (1.56) | 12.28 | |
| BAVA | Bavarian Nordic | 0.00 | 0 per month | 0.00 | (0.18) | 3.45 | (3.76) | 21.30 | |
| GN | GN Store Nord | 0.00 | 0 per month | 0.00 | (0.22) | 3.31 | (3.56) | 8.21 | |
| FLS | FLSmidth Co | 0.00 | 0 per month | 1.52 | (0.0005) | 2.68 | (2.44) | 8.11 |
Genmab AS Additional Predictive Modules
Most predictive techniques to examine Genmab price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Genmab using various technical indicators. When you analyze Genmab charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Genmab AS Predictive Indicators
The successful prediction of Genmab AS stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Genmab AS, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Genmab AS based on analysis of Genmab AS hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Genmab AS's related companies.
Story Coverage note for Genmab AS
The number of cover stories for Genmab AS depends on current market conditions and Genmab AS's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Genmab AS is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Genmab AS's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Genmab AS Short Properties
Genmab AS's future price predictability will typically decrease when Genmab AS's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Genmab AS often depends not only on the future outlook of the potential Genmab AS's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genmab AS's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 66 M | |
| Cash And Short Term Investments | 19.3 B |
Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Basic Forecasting Models to cross-verify your projections. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..